Skip to main content

Table 3 Biologic agent use in idiopathic and JIA uveitis

From: Medication use in juvenile uveitis patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance Registry

Drug Idiopathic Uveitis JIA Uveitis
N = 92 (%) N = 643 (%)
TNF inhibitor 49 (53) 353 (55)
 Adalimumab 18 (20) 196 (30)
 Certolizumab 0 (0) 1 (0.2)
 Etanercept 0 (0) 159 (25)
 Golimumab 1 (1) 3 (0.5)
 Infliximab 36 (39) 174 (27)
Abatacept 0 (0) 23 (4)
Anti-IL-1 0 (0) 9 (1.5)
 Anakinra 0 (0) 7 (0.2)
 Rilonacept 0 (0) 1 (0.2)
 Canakinumab 0 (0) 1 (0.2)
Rituximab 0 (0) 4 (0.5)
Tocilizumab 0 (0) 4 (0.5)
  1. Data in this table represent “ever drug use” in patients with data available on biologic drug exposure (92/92 patients with idiopathic uveitis and 643/646 patients with JIA uveitis)
  2. JIA juvenile idiopathic arthritis